The type 2 diabetes treatment armamentarium has a place for Novo Nordisk AS's proposed combination product, but FDA should try to more definitively to determine which patients would ideally benefit, advisory committee members concluded.
Novo Nordisk has proposed an insulin and glucagon-like-peptide-1 agonist combination as an adjunct to diet and exercise to improve glycemic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?